As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

As­traZeneca’s PD-L1 Imfinzi failed a Phase III tri­al in non-small cell lung can­cer (NSCLC) when in­ves­ti­gat­ed con­cur­rent­ly with chemora­dio­ther­a­py (CRT) as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.